Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Employees10,000IPOJun 4, 2021SIC2834HQ30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
to
Financials (MXN)
Profitability
Metric
Current
Margins
Gross Margin
53.3%
Operating Margin
19.7%
EBITDA Margin
20.8%
Net Margin
3.0%
OCF Margin
—
FCF Margin
6.1%
Returns on Capital
ROE
27.5%
ROA
1.4%
ROIC
5.4%
ROCE
8.8%
ROC (Greenblatt)
37.0%
3Y ROIIC
−39.3%
Consistency
Years Profitable / 10Y
8
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
9.30
Forward P/E
2.01
P/E ex-NRI
1.80
Shiller P/E (CAPE)
—
Cash Flow Multiples
P/FCF
4.48
P/OCF
2.46
P/Owner Earnings
153.59
FCF Yield
22.71%
Enterprise Value Multiples
EV / EBIT
10.59
EV / Forward EBIT
—
EV / EBITDA
7.63
EV / Forward EBITDA
—
EV / Revenue
1.58
EV / Forward Revenue
—
Asset / Sales
P/S
0.28
P/B
2.29
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
1.22%
Forward Dividend Yield
1.15%
3Y Dividend Growth
−32.8%
Payout Ratio
0.10
5Y Yield on Cost
1.22%
Buybacks & Dilution
3Y Buyback Ratio
−0.80%
5Y Share Change
3.2%
Combined
Shareholder Yield
−3.50%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
11.50
Gross Debt / EBITDA
6.70
Cash / Debt
0.07
Equity / Assets
0.06
Coverage
Interest Coverage
2.43
Short-Term Liquidity
Current Ratio
1.82
Quick Ratio
1.23
Cash Ratio
0.24
Composite Scores
Piotroski F-Score
5
Altman Z-Score
1.11
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-02-23
$0.02
2026-03-12
2025-11-20
$0.02
2025-12-11
2025-08-15
$0.02
2025-09-11
2025-05-12
$0.02
2025-06-12
2025-02-24
$0.28
2025-03-13
2024-11-12
$0.28
2024-12-12
2024-08-16
$0.28
2024-09-12
2024-05-10
$0.28
2024-06-13
2024-02-23
$0.28
2024-03-14
2023-11-10
$0.28
2023-12-14
10 of 19
View allDate
Transcript
Type
2026-07-23
Organon & Co Extraordinary Shareholders Meeting Transcript
Shareholders and Annual Meetings
2026-06-09
Organon & Co Annual Shareholders Meeting Transcript
Shareholders and Annual Meetings
2026-02-12
Q4 2025 Organon & Co Earnings Call Transcript
Earnings Call
2025-12-03
Organon & Co at Piper Sandler Healthcare Conference Transcript
Conference Presentations
2025-11-10
Q3 2025 Organon & Co Earnings Call Transcript
Earnings Call
2025-08-05
Q2 2025 Organon & Co Earnings Call Transcript
Earnings Call
2025-05-01
Q1 2025 Organon & Co Earnings Call Transcript
Earnings Call
2025-02-13
Q4 2024 Organon & Co Earnings Call Transcript
Earnings Call
2024-10-31
Q3 2024 Organon & Co Earnings Call Transcript
Earnings Call
2024-08-06
Q2 2024 Organon & Co Earnings Call Transcript
Earnings Call
10 of 30
5-Step DuPont Analysis
ROE %
32.90%
×
×
Net Margin %
3.22%
×
×
Operating Margin %
19.80%
Operating Income
MX$23.66B
÷
Revenue
MX$119.50B
×
Tax Burden
0.4601
Net Income
MX$3.84B
÷
Pretax Income
MX$8.35B
×
Interest Burden
0.3531
Pretax Income
MX$8.35B
÷
Operating Income
MX$23.66B
×
Asset Turnover
0.48
÷
Revenue
MX$119.50B
÷
Average Total Assets
MX$251.07B
Begin Total Assets
MX$266.91B
End Total Assets
MX$235.22B
×
Equity Multiplier
21.49
÷
Avg Total Assets
MX$251.07B
÷
Avg Stockholders Equity
MX$11.68B
Begin Equity
MX$9.62B
End Equity
MX$13.75B